Citigroup Maintains Neutral on Hims & Hers Health, Lowers Price Target to $33
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Daniel Grosslight maintains Hims & Hers Health (NYSE:HIMS) with a Neutral and lowers the price target from $35 to $33.
Citigroup analyst Daniel Grosslight maintains Hims & Hers Health (NYSE:HIMS) with a Neutral and lowers the price target from $35 to $33.